Introducing Tresiba® (insulin degludec [rDNA origin] injection)

Understanding the formulation strength your healthcare professional has prescribed





# What is Tresiba® and what is it used for

Tresiba $^{\otimes}$  is a once-daily basal insulin analogue. Tresiba $^{\otimes}$  is used to treat diabetes mellitus in adults, adolescents and children from the age of 1 year. It helps your body reduce your blood sugar level. Tresiba $^{\otimes}$  is used for once-daily dosing. For occasions when you cannot follow your regular dosing schedule you can change the time of dosing however this change in dosing should be discussed with your health care professional. Always ensure a minimum of 8 hours between injections.

## **Two Tresiba® Formulation Strengths**

Tresiba® comes in two formulation strengths: 100 units/mL and 200 units/mL. Tresiba® 200 units/mL FlexTouch® pen has twice as many insulin units in each mL. Your healthcare provider will prescribe the formulation strength that is right for you.

Both devices have a dose counter window that shows the exact dose dialled. This means that the dose shown in the window is the dose that will be delivered regardless of formulation strength. Always use the dose counter to select the dose. Do not count clicks. Dose conversion should not be done if you move from one formulation strength to another. Check how many units were selected before injecting Tresiba®.








### **Recognising Your Prescribed Strength**

It is important to be sure you are using the correct formulation strength prescribed by your healthcare provider. "Tresiba® 100 units/mL" or "Tresiba® 200 units/mL" is clearly marked on the pen label and packaging.

Additionally, Tresiba<sup>®</sup> 100 units/mL packaging and label are light green, and Tresiba<sup>®</sup> 200 units/mL packaging and label are dark green with striping. The Tresiba<sup>®</sup> 200 units/mL label and packaging also have a red box highlighting the formulation strength.





If you are colour blind, you can recognize Tresiba® 200 units/mL by the two raised dots push button.



Tresiba® 100 units/mL



Tresiba® 200 units/mL



### **Avoiding mix-ups**

If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. It is advisable to seek help from a person with good eyesight who is trained to use Tresiba®.

If you are a parent or care giver of a patient taking Tresiba<sup>®</sup>, please ensure that their doctor or nurse has trained you on how to use Tresiba<sup>®</sup>.

Always check the insulin label when you receive it at the pharmacy and before each injection to avoid accidental mix-ups between different formulation strengths of Tresiba® as well as other insulin products you may be taking.

Using the wrong insulin formulation strength or product could potentially cause you to take too much or too little insulin. Too much insulin can lead to hypoglycemia, or low blood sugar. Talk to your healthcare professional for more information.

Adverse reactions to Tresiba®, including medication errors, should be reported to Novo Nordisk on 01 862 9700. You can also report side effects directly via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Always use this medicine exactly as your doctor has told you. Follow all instructions in the package leaflet. Check with your healthcare professional, pharmacist or nurse if you need help.

#### Who should not take Tresiba®

• The contraindications for use of Tresiba<sup>®</sup> are included in the label. If you have any queries regarding this information, please discuss with your healthcare professional.

The Apis bull logo, Changing Diabetes®, Tresiba® and FlexTouch® are registered trademarks of Novo Nordisk A/S. Date of preparation: January 2023; IE23TSM00003



